- 1 Could Metformin use reduce abdominal aortic aneurysm risk? A Mendelian randomisation
- 2 study using known Metformin targets

3 Authors:

- 4 Katie L Saxby MSc¹, Frank Dudbridge PhD^{2,3}, Nilesh J Samani MD^{1,2}, Matthew J Bown MD^{1,2},
- 5 Christopher P Nelson PhD^{1,2}
- ⁶ ¹Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
- 7 ²NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United
- 8 Kingdom.
- ³Department of Population Health Sciences, University of Leicester, Leicester, United
 Kingdom.
- 11
- Corresponding author: Katie L Saxby, kls46@leicester.ac.uk, Cardiovascular Research
 Centre, Glenfield Hospital, Groby Road, Leicester, LE3 9QP.
- 14

15 Abstract:

16

17 Introduction: An abdominal aortic aneurysm (AAA) is a swelling of the main artery in the

- 18 body estimated to affect 0.92% of adults (aged 30-79) worldwide. Rupture is often fatal and
- surgical intervention may be offered if the risk of rupture is high. There is no treatment to
 prevent AAA or to slow aneurysm growth aside from dietary and lifestyle recommendations.
- 21 Metformin, a drug prescribed to treat type 2 diabetes, has previously been associated with a
- 22 potential reduction in AAA disease risk but no causal link has been shown. Here we
- investigate the causal link between Metformin and AAA risk through Mendelian
- 24 randomisation (MR).
- 25 **Methods:** We conducted a two-sample MR analysis using genetic variants associated with
- 26 gene expression of five Metformin drug targets that also show a genetic association with

27 decreased glycated haemoglobin (HbA1c) levels. Effect sizes are obtained from within UK

Biobank for HbA1c, and within AAAgen for AAA risk, a multi-ancestry meta-GWAS analysis of 39,221 cases and 1,086,107 controls.

- 30 **Results:** We identified statistically significant evidence of a causal association between a
- 31 genetic proxy for Metformin action and a decrease in AAA risk, OR=0.58 (95%CI: 0.37-0.90
- 32 p=0.015). We estimate that on average a one standard deviation decrease in HbA1c,
- measured via Metformin gene targets, reduces AAA risk by over 40%.
- 34 **Conclusion:** Metformin use in those at increased risk of AAA may reduce incidence of
- disease. Clinical trials are required to assess the efficacy of Metformin in reducing disease
- 36 risk.

1	Introduction: The only current treatment for abdominal aortic aneurysm (AAA) is surgical		
2	repair, which is associated with significant morbidity and mortality. Patients not fit enough		
3	for surgery have no treatment options. For people with small AAA there are no treatments		
4	to slow AAA growth and prevent the need for surgery in the future.		
5	Diabetes is associated with reduced AAA risk but to date no evidence of a causal		
6	association has been found. Observational studies have shown that Metformin, a drug		
7	prescribed to lower glycated haemoglobin (HbA1c) in diabetics, is also associated with a		
8	reduction in AAA disease risk and reduced growth(1) and may be the driver of the reduced		
9	risk seen in people with diabetes. Whilst randomised trials are currently underway to test		
10	the effectiveness of metformin to prevent AAA progression(2,3), these are based on		
11	observational data and no causal link has been demonstrated. Here we utilise genetic		
12	variants to investigate the potential for a causal association between Metformin and AAA		
13	risk through Mendelian randomisation (MR).		
14	Methods: We conducted MR using published instruments of genetic variants for known		
15	Metformin targets. Variants were identified through associated expression of genes		
16	involved in the action of these targets that also associated with HbA1c levels(4). This		
17	resulted in five instruments consisting of a total of 32 variants near 22 genes. The		
18	instruments represent Metformin's HbA1c lowering effect.		
19	Effect sizes were independently estimated in European-ancestry subjects within UK		
20	Biobank (n=344,182) and represent changes in Z-standardised HbA1c where a unit change is		
21	estimated as 1.09% (~6.75mmol)(4). This amount is consistent with the effect size estimated		
22	in a systematic review of Metformin monotherapy; 1.12% (95%CI: 0.92-1.32)(5).		

2

Effect sizes and standard error estimates for AAA risk were obtained from AAAGen, 1 2 the largest genetic study on AAA risk to date: a multi-ancestry (European and African) meta-3 GWAS of 39,214 cases and 1,086,107 controls(6). MR was conducted using the inverse variance weighted (MR-IVW) method(7) as our 4 5 primary analysis for each individual target and also using an instrument of the five targets 6 combined. To assess potential weak instrument bias or pleiotropy we applied MR-Egger, 7 weighted-median, weighted-mode, MR-RAPS and MR-PRESSO as sensitivity analyses to the 8 combined instrument(7). Effect estimates were compared across methods for evidence of 9 consistency. To assess the specificity of the Metformin pathway we also assessed a genome-10 wide HbA1c instrument sourced from the same paper(4). **Results:** Of the 32 independent variants ($r^2 < 0.01$) we found 31 available within AAAgen. 11 12 Analysing each target revealed consistent protective effects against AAA risk (Figure panel 13 A). The combined instrument of 31 variants found statistically significant evidence (p=0.015) of a causal association between the HbA1c lowering effects across the five Metformin 14 15 targets and a decrease in AAA risk. The combined instrument estimates a 43% reduction in risk due to a 1.09% decrease in HbA1c OR=0.57 (95%CI: 0.37-0.90). There was a small 16 17 amount of overlap between the exposure and outcome samples, as AAAGen included UK Biobank AAA cases and up to 22,049 controls as part of the meta-analysis and the HbA1c 18 19 effect sizes are estimated within UK Biobank. However, this is anticipated to have minimal 20 effect on the estimates, except for MR-Egger, when using Biobank sized data(8). We also note a potential for increased heterogeneity between the datasets due to mixed ancestry, 21 22 although allele frequencies between included samples were found to be consistent(6).

3

All sensitivity analyses were applied to the combined instrument due to the limited number of genes in each individual target and show strong consistency of effect size and direction (**Figure** panel **B**). The MR-Egger test for a non-zero intercept was not statistically significant (p=0.362) suggesting no evidence of pleiotropy. MR analysis using the genomewide HbA1c instrument showed no evidence of a causal association with AAA risk, OR=1.02 (95%CI: 0.98-1.06).

7 **Discussion:** This study used genetic instruments to assess the potential therapeutic benefit 8 of Metformin in reducing AAA risk via known Metformin targets. We provide evidence that 9 Metformin has the potential to reduce AAA risk through target-specific HbA1c lowering mechanisms. Results were consistent across targets and sensitivity analyses. The desired 10 11 reduction in HbA1c to achieve this risk reduction is within the estimated pharmacological 12 effect of a clinical Metformin dose. While we have not shown a direct effect on AAA 13 progression, the inferred benefit of Metformin treatment provides additional justification 14 for ongoing clinical trials (2,3). Critically, no evidence of association with AAA risk was found 15 using a whole-genome HbA1c instrument, giving further evidence to the specificity of an HbA1c change due to Metformin targets. 16

We acknowledge that the validity of the instrument and its suitability to represent Metformin effects has attracted comment and criticism(9,10). It is highly likely that there are Metformin pathways that have not have been captured here. Other pathways may counteract these protective effects and nullify or, even worse, cause harm and increase AAA risk. Whilst this is possible, it would be inconsistent with findings seen in observational studies. However, we recognise that this paper is limited to reporting results on five known

4

1 targets and that further work is required to be able to weight these correctly to obtain a

2 more accurate combined effect estimate.

3	We also note that the instrument was constructed on postulated downstream		
4	effects of Metformin on glycaemic levels via known Metformin targets, and we cannot		
5	evaluate the effect of Metformin therapy in clinical practice(10). We have so far been unable		
6	to identify a suitable and meaningful positive control and therefore cannot confirm that the		
7	targets are a representation of the true Metformin effect.		
8	Findings from clinical trials currently in progress to assess the impact of Metformin		
9	on AAA growth and risk of serious outcome(2,3) will soon help to shed light on what is		
10	difficult to ascertain here: that is, whether these targets represent a valid Metformin		
11	instrument or if the effects could be cancelled out by unaccounted pathways. With no		
12	medication currently available to reduce AAA risk or slow disease progression, we remain		
13	hopeful that our findings, in alignment with those seen in observational studies, will confirm		
14	that Metformin may prove to be a viable treatment option.		

1 Funding

- 2 This research was funded in whole, or in part, by the Wellcome Trust (grant number
- 3 222959/Z/21/Z) to KLS. For the purpose of open access, the author has applied a CC BY
- 4 public copyright licence to any Author Accepted Manuscript version arising from this
- 5 submission; British Heart Foundation (grant numbers CD/14/2/30841 and RG/18/10/33842
- 6 to MJB, FD, CPN); and British Heart Foundation (grant number CH/F/22/90014) to MJB.
- 7

8 References


9 1) Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J et al. Association 10 between metformin prescription and growth rates of abdominal aortic aneurysms. Br J 11 Surg 2017;104:1486-1493. 2) Lareyre F, Raffort J. Metformin to Limit Abdominal Aortic Aneurysm Expansion: Time for 12 Clinical Trials. Eur J Vasc Endovasc Surg 2021;61:1030. 13 14 3) Golledge J, Arnott C, Moxon J, Monaghan H, Norman R, Morris D et al. Protocol for the 15 Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether 16 metformin reduces the risk of serious complications of abdominal aortic aneurysm. Current controlled trials in cardiovascular medicine; Trials 2021;22:962. 17 4) Zheng J, Xu M, Walker V, Yuan J, Korologou-Linden R, Robinson J et al. Evaluating the efficacy 18 19 and mechanism of metformin targets on reducing Alzheimer's disease risk in the general 20 population: a Mendelian randomisation study. *Diabetologia* 2022;65:1664-1675. 21 5) Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin 22 treatment and dose on glycemic control. Diabetes Care 2012;35:446-454. 23 6) Roychowdhury T. et al. Multi-ancestry GWAS deciphers genetic architecture of abdominal 24 aortic aneurysm and highlights PCSK9 as a therapeutic target. 2022; Nature Genetics 2023; 25 doi 10.1038/s41588-023-01510-y. 7) Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM et al. Guidelines for 26 27 performing Mendelian randomization investigations. Wellcome open research; Wellcome 28 Open Res 2019;4:186. 29 8) Minelli C, Del Greco M F, van der Plaat D,A., Bowden J, Sheehan NA, Thompson J. The use of 30 two-sample methods for Mendelian randomization analyses on single large datasets. Int J 31 Epidemiol 2021;50:1651-1659. 32 9) Anderson EL, Williams DM. Drug target Mendelian randomisation: are we really 33 instrumenting drug use? Diabetologia 2023;66:1156-1158. 34 10) Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V et al. Using genetic 35 association data to guide drug discovery and development: Review of methods and 36 applications. Am J Hum Genet 2023;110:195-214. 37

- 1 Legends
- 2 *Non-targeted-whole-genome HbA1c instrument
- 3 Figure: Associations between genetically predicted HbA1c levels via 22 genes / 31 variants and
- 4 abdominal aortic aneurysm risk from two-sample Mendelian randomisation analyses. Where n
- 5 genes indicates the number of genes in each pathway. Odds ratio (OR) estimates represent a 1.09%
- 6 decrease (~6.75mmol/mol or 1 s.d.) in HbA1c. Panel A: Primary analysis of individual Metformin-
- 7 drug target pathways estimated using MR-IVW, combined pathways of 31 genetic variants in the
- 8 instrument, and genome-wide HbA1c estimate using inverse weighted variance method showing OR
- 9 and 95% confidence intervals. **Panel B:** Sensitivity analysis of the combined 31 variant instrument.
- 10 The MR-PRESSO estimate represents IVW after the removal of two potential outlier variants.


Metformin-target	n genes
Growth differentiation factor 15 (GDF15)	1
Mitochondrial glycerol-3 (MG3)	1
AMP-activated protein kinase (AMPK)	2
Glucagon (GCG)	1
Mitochondrial complex I (MCI)	17
Five pathways combined (MR-IVW)	22
HbA1c* (MR-IVW)	
	Growth differentiation factor 15 (GDF15) Mitochondrial glycerol-3 (MG3) AMP-activated protein kinase (AMPK) Glucagon (GCG) Mitochondrial complex I (MCI) Five pathways combined (MR-IVW)

Α

в



Method	n variants
MR Egger	31
Weighted mode	31
Weighted median	31
Robust adjusted profile score (RAPS)	31
MR PRESSO	29



Odds ratio (95% CI)	p-value
0.20 (0.03-1.42)	0.109
0.20 (0.03-1.42)	0.108
0.57 (0.12-2.66)	0.478
 0.61 (0.02-22.15)	0.790
0.60 (0.36-0.99)	0.046
0.57 (0.37-0.90)	0.015
1.02 (0.98-1.06)	0.333

Odds ratio (95% CI)	p-value
0.83 (0.34-2.06)	0.695
0.45 (0.29-0.70)	0.0014
0.47 (0.31-0.71)	0.0037
0.54 (0.40-0.73)	<0.0001
0.48 (0.34-0.68)	0.0003

- 2.0 1.41